


A person wearing a white lab coat is shown from the chest down, holding a smartphone in their right hand. The background is a dark blue grid of glowing dots in various colors (green, purple, blue), resembling a digital data visualization or a server room. The overall scene suggests a focus on technology, data, and professional work.

FINANCING FURTHER GROWTH AMBITIONS

Michael Rauch

Attractive revenue growth with strong margin development



EBITDA 2019 pro forma, 2020 adjusted

■ Total revenues ■ Thereof recurring



Continued high performance in LTM – even during Covid-19 pandemic

Group	LTM 06/20		Ambulatory Information Systems		Pharmacy Information Systems		Hospital Information Systems		Consumer & Health Management Information Systems	
	Revenue (€m)	YOY	Revenue Share	YOY	Revenue Share	YOY	Revenue Share	YOY	Revenue Share	YOY
Revenue (€m)	747	+3%	59 %	-1%	16 %	+7%	19 %	+11%	6 %	+19%
EBITDA adjusted (€m)	192	+5%		-1%		+10%		+41%		+57%
Margin	26%	+1ppt		Oppt		+1ppt		+3ppt		+6ppt

Strong underlying organic growth across the group

H1/20 vs. H1/19

GROUP	-2%	+7% ex TI
AIS	-7%	+8% ex TI
PCS	+6%	
HIS	+4%	
CHS	+9%	

Guidance FY 2020
for organic growth
(as raised on Aug 6)

2-6% yoy
(incl. TI)

Underlying organic
growth expected going
forward

Low to mid single-
digit percentage
range



TI approval reflected in updated guidance (now also including HIS acquisition)

€m	Full-year guidance (Feb 5, 2020)		Updated guidance (Aug 6, 2020)		Full-year guidance (Feb 5, 2020)		Updated guidance (Aug 6, 2020)	
Group revenues	765 – 815		820 – 860	Segments	AIS revenues	453 – 485		470 – 490
Adj. EBITDA	195 – 215		205 – 220		PCS revenues	124 – 134		124 – 134
Organic growth (group revs in %)	0 – 6		2 – 6		HIS revenues	142 – 148		180 – 188
					CHS revenues	46 – 48		46 – 48

Guidance reflects management's best estimate based on the currently available information, particularly with regard to COVID-19 and the further rollout of Telematics Infrastructure.

Preparing for further growth ambitions


Favourable funding conditions



Successful share placement

- ✓ **10%** placement June 2020
 - 9% treasury shares
 - 1% capital increase
- ✓ Cash proceeds **€340m**

New legal form




- ▶ **Additional headroom** for further strategic steps
- ▶ **Improved financial position** – equity ratio now >40%
- ▶ **Preserving the entrepreneurial culture and perspective**

Building on fast deleveraging competence

Recent larger acquisitions

QUALIZORG	2019 ~€10m
MEDISTAR DISTRIBUTORS	2019 ~€25m
EPSILOG, H&S	2019 ~€80m
MEDICO, SHA, SELENE	2020 ~€200m


Leverage



With increased investment into R&D ...

R&D spending (incl. CAPEX)

€m




% of revenues

20%

19%

EBITDA (less R&D Capex)

€m



EBITDA Margin

21%

26%

... to deliver best-in-class solutions to all healthcare providers
while at the same time increase the profit pool for our shareholders

**NOBODY SHOULD
SUFFER OR DIE
BECAUSE
AT SOME POINT
MEDICAL INFORMATION
WAS MISSING**

- ▶ **Strong market positions** across businesses & regions
- ▶ Proven **crisis-resilience** with **>60% of revenues recurring**
- ▶ **Continuously investing** in customer benefits (R&D spend)
- ▶ **Sustainable EBITDA growth** with **strong cash flow profile**
- ▶ Excellent track record in **value enhancing M&A**
- ▶ **Increased flexibility** following successful share placement
- ▶ Further enhancing **value generation & shareholder return**